Related Experiment Video

Updated: Sep 21, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.4K

Reduced Angiopoietin Factor 2 Levels Are Correlated with Better Cardiac Function and Prognosis in Valvular Heart

Jian Hou1,2, Xiaolin Huang1,2, Liqun Shang1,2

  • 1Department of Cardiac Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, People's Republic of China.

Brazilian Journal of Cardiovascular Surgery
|June 3, 2022
PubMed

Insights

Reduced Angiopoietin-2 (Ang2) levels are linked to valvular heart disease and predict short-term mortality. Ang2 may be a key therapeutic and prognostic target for this condition.

Area of Science:

  • Cardiovascular Medicine
  • Biomarker Discovery
  • Inflammation Research

Background:

  • Valvular heart disease lacks established circulating biomarkers.
  • Angiopoietin-1 (Ang1), Angiopoietin-2 (Ang2), and vascular endothelial growth factor (VEGF) are inflammation-associated cytokines.
  • Investigating these cytokines' role in valvular heart disease is crucial.

Purpose of the Study:

  • To investigate the clinical significance of Ang1, Ang2, and VEGF in valvular heart disease.
  • To explore the association between these cytokines and disease severity.
  • To identify potential biomarkers for short-term mortality in valvular heart disease patients.

Main Methods:

  • Retrospective study including 42 valvular heart disease patients and 20 healthy controls.
  • Plasma levels of Ang1, Ang2, and VEGF measured using enzyme-linked immunosorbent assays.
  • Logistic regression analysis to determine predictors of short-term mortality.

Main Results:

  • Ang2 levels were significantly decreased in valvular heart disease patients compared to controls (P=0.023).
  • Decreased Ang2 levels were observed in patients with NYHA class I/II (P=0.017) but not NYHA class III/IV (P=0.485).
  • Ang2 independently predicted short-term mortality (OR 18.75, P=0.033). Ang1 and VEGF showed significant correlations with Ang2 and each other.

Conclusions:

  • Angiopoietin-2 (Ang2) may serve as a potential therapeutic and prognostic biomarker in valvular heart disease.
  • Further research is warranted to validate Ang2's role in disease management.
  • Understanding cytokine profiles can improve patient outcomes.
Abstract

Keywords:
Angiopoietin 1Angiopoietin 2CytokinesHeart Valve DiseasesInflammationValvular Heart Disease

More Related Videos

In Vitro Model of Coronary Angiogenesis08:03

In Vitro Model of Coronary Angiogenesis

Published on: March 10, 2020

7.9K
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.4K

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
229
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
62
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
527
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
54